Open AccessBalancing the Risks and Benefits of Long‐Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications
Author(s) -
Alfredsson Joakim,
Roe Matthew T.
Publication year - 2015
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.115.001897
Subject(s) - medicine , intensive care medicine , disease , atherosclerotic cardiovascular disease
Thrombin is a key stimulus for fibrin generation as well as a potent platelet activator through interaction with protease‐activated receptors on the platelet surface.[1][1] Vorapaxar is a reversible and selective inhibitor of the PAR‐1 receptor, the major thrombin receptor on platelets, and has